Related Experiment Video
Updated: Aug 4, 2026
Primary Orthotopic Glioma Xenografts Recapitulate Infiltrative Growth and Isocitrate Dehydrogenase I Mutation
Published on: January 14, 2014
Updates in IDH-Wildtype Glioblastoma
Jawad M Melhem1, Jay Detsky2, Mary Jane Lim-Fat1
1Division of Neurology, Department of Medicine, Faculty of Medicine, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Canada.
Abstract:
Glioblastoma is the most aggressive primary brain tumor with a poor prognosis. The 2021 WHO CNS5 classification has further stressed the importance of molecular signatures in diagnosis although therapeutic breakthroughs are still lacking. In this review article, updates on the current and novel therapies in IDH-wildtype GBM will be discussed.
Insights
Glioblastoma (GBM) is an aggressive brain tumor. This review covers current and novel therapies for IDH-wildtype GBM, highlighting the need for better treatments despite advances in molecular diagnostics.
Area of Science:
- Neuro-oncology
- Molecular Diagnostics
- Cancer Therapeutics
Background:
- Glioblastoma (GBM) is the most aggressive primary brain tumor, characterized by a poor prognosis.
- The 2021 World Health Organization (WHO) CNS5 classification emphasizes molecular signatures for GBM diagnosis.
- Despite diagnostic advancements, significant therapeutic breakthroughs for GBM remain limited.
Purpose of the Study:
- To review current and emerging therapeutic strategies for IDH-wildtype Glioblastoma.
- To provide an update on the treatment landscape for this challenging brain cancer.
- To highlight areas for future therapeutic development in GBM.
Main Methods:
- Comprehensive literature review of recent studies on GBM therapies.
- Analysis of current treatment guidelines and clinical trial outcomes.
- Focus on therapies targeting IDH-wildtype Glioblastoma.
Main Results:
- Current therapies for IDH-wildtype GBM offer limited survival benefits.
- Novel therapeutic approaches, including targeted therapies and immunotherapies, show promise.
- Molecular profiling is crucial for guiding treatment decisions.
Conclusions:
- There is an urgent need for more effective therapies for IDH-wildtype GBM.
- Advances in understanding GBM molecular biology are paving the way for personalized treatments.
- Continued research into novel therapeutic strategies is essential to improve patient outcomes.
